Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ferozsons LaboratoriesKAR:FEROZ -2.38%70 OCF Yield % is 3.18 as of Jul. 14, 2026, which is 54% below its 10-year median of 6.94. GuruFocus rates KAR:FEROZ with a GF Score™ of 70/100 and a GF Value™ of ₨419.78 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Ferozsons Laboratories ranks worse than 51.44% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Ferozsons Laboratories OCF Yield % Related Terms
Ferozsons Laboratories OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:FEROZ vs ZTS, UTHR, VTRS: OCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ferozsons Laboratories's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ferozsons Laboratories OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ferozsons Laboratories's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Ferozsons Laboratories's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ferozsons Laboratories (KAR:FEROZ) has a OCF Yield % of 3.18 as of Jul. 14, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Ferozsons Laboratories and its competitors. This is 54% below median its historical median of 6.94. According to the industry distribution chart, Ferozsons Laboratories ranks #518 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 51.4%.
Is Ferozsons Laboratories' OCF Yield % too high?
Ferozsons Laboratories' current OCF Yield % of 3.18 is 54% below median its 10-year median of 6.94. The Drug Manufacturers industry median OCF Yield % is 3.53. Ferozsons Laboratories' value of 3.18 is 9.9% below this industry median. Based on the distribution chart, Ferozsons Laboratories ranks #518 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Ferozsons Laboratories has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ferozsons Laboratories' OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ferozsons Laboratories ranks #518 out of 1007 companies for OCF Yield %. This places Ferozsons Laboratories in the lower half of its industry. The industry median OCF Yield % is 3.53. Ferozsons Laboratories' value of 3.18 is 9.9% below this benchmark. While the company's 10-year median is 6.94 vs. the industry median of 3.53, Ferozsons Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.53, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ferozsons Laboratories's current OCF Yield % of 3.18 is 9.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Ferozsons Laboratories and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ferozsons Laboratories's current OCF Yield % is 3.18, which is 54% below median its own 10-year median of 6.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ferozsons Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ferozsons Laboratories (KAR:FEROZ) is currently considered Fairly Valued. The stock's GF Value™ is ₨419.78, compared to a current price of ₨391.89 — trading 6.6% below its estimated fair value. The current OCF Yield % is 3.18, which is 54% below median its 10-year median of 6.94 and 9.9% below the Drug Manufacturers industry median of 3.53. Ferozsons Laboratories' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Ferozsons Laboratories (KAR:FEROZ), the current OCF Yield % is 3.18 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ferozsons Laboratories (KAR:FEROZ) Overvalued in 2026?
Based on GuruFocus' analysis, Ferozsons Laboratories stock appears to be undervalued.
The current stock price of ₨391.89 is trading 6.6% below its estimated GF Value™ of ₨419.78.
GuruFocus considers Ferozsons Laboratories to be Fairly Valued.
Key valuation signals for KAR:FEROZ:
OCF Yield %: 3.18 (54% below median its 10-year median of 6.94)
GF Value™: ₨419.78 vs. price of ₨391.89 (6.6% below fair value)
Industry Position: 9.9% below the Drug Manufacturers median (#518 of 1007)
No single metric tells the full story. See the KAR:FEROZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ferozsons Laboratories Ltd is a pharmaceutical company. It is engaged in the import, manufacture, and sale of pharmaceuticals products and medical devices. The company operates in the therapeutic areas of dermatology, anti-infective treatments, gastroenterology, hepatology, cardiology, and diabetes. It manufactures tablets, capsules, syrups, suspensions, creams, and ointments. The company operates in three segments namely Ferozsons, BF Biosciences, and Others. The group sells its products in Pakistan and internationally, of which the majority of the revenue is generated from the sales made in Pakistan.
70GF Score
Get the complete analysis for KAR:FEROZ
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:FEROZ has been successfully added to your 
